Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Universitat de València, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, National Cancer Centre Japan, National Cancer Center Hospital East, Winship Cancer Institute, Washington University in St. Louis, University of Würzburg, Universitätsklinikum Würzburg, Clinica Universidad de Navarra, Hospital Del Mar, Hospital del Mar Research Institute, Boehringer Ingelheim (Germany), Boehringer Ingelheim (France), University Hospital Cologne, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814412